Domain > bphmeds.net

Welcome! Right click nodes and scroll the mouse to navigate the graph.

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2015-04-16	85.25.228.22 (ClassC)
2025-01-11	37.1.212.62 (ClassC)

Port 80

HTTP/1.1 200 OKServer: nginxDate: Sat, 11 Jan 2025 10:51:06 GMTContent-Type: text/html; charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveKeep-Alive: timeout60X-Powered-By: PHP/5.4.45

!DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd>html xmlnshttp://www.w3.org/1999/xhtml langen-US>	head profilehttp://gmpg.org/xfn/11>		meta http-equivContent-Type contenttext/html; charsetUTF-8 />		title> Buy Blood Pressure/Heart Drugs without Prescription/title>		link relstylesheet hrefhttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/style.css typetext/css mediascreen />		link relstylesheet hrefhttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/ie.css typetext/css mediascreen />		link relshortcut icon hrefhttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/favicon.ico />		script typetext/javascript srchttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/js/jquery-min.js>/script>		script typetext/javascript srchttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/js/spectrum-min.js>/script>		link relshortcut icon hreffavicon.ico />		link relpingback hrefhttp://bphmeds.net/xmlrpc.php />				link reldns-prefetch href//s.w.org />		script typetext/javascript>			window._wpemojiSettings  {baseUrl:https://s.w.org/images/core/emoji/2.2.1/72x72/,ext:.png,svgUrl:https://s.w.org/images/core/emoji/2.2.1/svg/,svgExt:.svg,source:{concatemoji:http://bphmeds.net/wp-includes/js/wp-emoji-release.min.js?ver4.7.2}};			!function(a,b,c){function d(a){var b,c,d,e,fString.fromCharCode;if(!k||!k.fillText)return!1;switch(k.clearRect(0,0,j.width,j.height),k.textBaselinetop,k.font600 32px Arial,a){caseflag:return k.fillText(f(55356,56826,55356,56819),0,0),!(j.toDataURL().length3e3)&&(k.clearRect(0,0,j.width,j.height),k.fillText(f(55356,57331,65039,8205,55356,57096),0,0),bj.toDataURL(),k.clearRect(0,0,j.width,j.height),k.fillText(f(55356,57331,55356,57096),0,0),cj.toDataURL(),b!c);caseemoji4:return k.fillText(f(55357,56425,55356,57341,8205,55357,56507),0,0),dj.toDataURL(),k.clearRect(0,0,j.width,j.height),k.fillText(f(55357,56425,55356,57341,55357,56507),0,0),ej.toDataURL(),d!e}return!1}function e(a){var cb.createElement(script);c.srca,c.deferc.typetext/javascript,b.getElementsByTagName(head)0.appendChild(c)}var f,g,h,i,jb.createElement(canvas),kj.getContext&&j.getContext(2d);for(iArray(flag,emoji4),c.supports{everything:!0,everythingExceptFlag:!0},h0;hi.length;h++)c.supportsihd(ih),c.supports.everythingc.supports.everything&&c.supportsih,flag!ih&&(c.supports.everythingExceptFlagc.supports.everythingExceptFlag&&c.supportsih);c.supports.everythingExceptFlagc.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady!1,c.readyCallbackfunction(){c.DOMReady!0},c.supports.everything||(gfunction(){c.readyCallback()},b.addEventListener?(b.addEventListener(DOMContentLoaded,g,!1),a.addEventListener(load,g,!1)):(a.attachEvent(onload,g),b.attachEvent(onreadystatechange,function(){completeb.readyState&&c.readyCallback()})),fc.source||{},f.concatemoji?e(f.concatemoji):f.wpemoji&&f.twemoji&&(e(f.twemoji),e(f.wpemoji)))}(window,document,window._wpemojiSettings);		/script>		style typetext/css>img.wp-smiley,img.emoji {	display: inline !important;	border: none !important;	box-shadow: none !important;	height: 1em !important;	width: 1em !important;	margin: 0 .07em !important;	vertical-align: -0.1em !important;	background: none !important;	padding: 0 !important;}/style>link relhttps://api.w.org/ hrefhttp://bphmeds.net/wp-json/ />link relEditURI typeapplication/rsd+xml titleRSD hrefhttp://bphmeds.net/xmlrpc.php?rsd />link relwlwmanifest typeapplication/wlwmanifest+xml hrefhttp://bphmeds.net/wp-includes/wlwmanifest.xml /> meta namegenerator contentWordPress 4.7.2 />	!-- Global site tag (gtag.js) - Google Analytics -->script async srchttps://www.googletagmanager.com/gtag/js?idUA-177661234-1>/script>script>  window.dataLayer  window.dataLayer || ;  function gtag(){dataLayer.push(arguments);}  gtag(js, new Date());  gtag(config, UA-177661234-1);/script>/head>		body classhome blog>				div idheader>			div idlogo>				h1>					a hrefhttp://bphmeds.net/>img srchttp://bphmeds.net/wp-content/themes/spectrum-theme-package/spectrum-theme/images/logo.png altBuy Blood Pressure/Heart Drugs without Prescription />/a>				/h1>			/div>			div idsubscribe>				a hrefhttp://bphmeds.net/feed/ titleSubscribe to Buy Blood Pressure/Heart Drugs without Prescription RSS>Subscribe to Buy Blood Pressure/Heart Drugs without Prescription RSS/a>			/div>			div classpageList>				ul>									/ul>			/div>		/div>		div idmainWrap>			div idmain>				div idsiteDescription>					h2>											/h2>				/div>				div idcontent>				div classpost-1310 post type-post status-publish format-standard hentry tag-bleeding tag-hemophilia tag-pres idpost-1310>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ relbookmark titlePermanent Link to OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe>OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>06/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe/span>/span>/p>			/div>			div classentry>				p>Ipsen (Euronext : FR0010259150; IPN) and Inspiration Biopharmaceuticals, Inc. (Inspiration) announced that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug status for OBI-1 for the treatment of hemophilia. Final adoption of the opinion is expected from the European Commission later this year and subject to it being finally granted, the orphan drug status would trigger a 10-year market exclusivity to OBI-1 in the European Union after its marketing approval. The FDA also issued an Orphan Drug Designation for OBI-1 in March 2004. /p>p>Jean-Luc BÃ©lingard, Chairman and Chief Executive Officer of Ipsen said: “Our transaction with Inspiration in late January of this year expresses Ipsen’s long term strategy to create a world leading hemophilia franchise. We are honored that the Committee for Orphan Medicinal Products of the European Medicines Agency shares our view of the medical benefit provided by OBI-1 to the hemophilia community.” /p>p>John Taylor, Co-Founder and Chairman of Inspiration added: “We are pleased with the continued progress of OBI-1 as a new, innovative therapy in the treatment of unmet medical needs in hemophilia.” /p>p>About Hemophilia /p>p>Hemophilia, congenital or acquired, is a bleeding disorder caused by low levels or absence of a protein called a coagulation factor, essential for blood clotting. The two most common forms of hemophilia are types A and B. Hemophilia A is caused by a factor VIII deficiency and occurs in ~1 out of every 5,000 male births. Hemophilia B is caused by factor IX deficiency and occurs in ~1 out of every 30,000 male births. Approximately 60% of persons with hemophilia have a severe condition, which results in frequent spontaneous bleeding episodes in addition to serious bleeding after injuries. The market for hemophilia treatment is 7.5 billion dollars annually. /p>p>About OBI-1 /p>p>About a third of patients with congenital hemophilia A and patients with acquired hemophilia develop an immune reaction to human forms of FVIII (hFVIII) and can no longer respond to human Factor VIII. Since OBI-1 possesses low cross reactivity to anti-hFVIII antibodies, it is expected that OBI-1 can provide therapeutic benefits to patients who are not able to use hFVIII. /p>p>OBI-1, a recombinant B-domain deleted FVIII bioengineered for low cross reactivity to anti-human FVIII inhibitors based on the porcine amino acid sequence, has recently been tested in a Phase II trial. OBI-1 was administered to patients with congenital hemophilia A complicated by the presence of human FVIII inhibitors experiencing a non-life/non-limb threatening bleed. A total of 25 bleeding episodes in 9 patients were treated with OBI-1, and all were successfully controlled. One subject had a mild infusion reaction and when re-treated for a subsequent bleed the subject did not report any adverse event. Eight out of nine (89%) subjects developed anti-pFVIII antibodies following exposure to OBI-1 and in subjects receiving repeated OBI-1 treatment higher anti-pFVIII titres did not affect efficacy or safety. The study demonstrated that OBI-1 is well-tolerated and can be given as a short infusion. OBI-1 is expected to enter phase III in 2010. /p>p>Source:br />Ipsen br />Inspiration Biopharmaceuticals/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/bleeding/ reltag>Bleeding/a>/li>li>a hrefhttp://bphmeds.net/tag/hemophilia/ reltag>Hemophilia/a>/li>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&titleOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&titleOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&titleOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe+http://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&titleOBI-1+Developed+By+Ipsen+And+Inspiration+Has+Obtained+A+Positive+Opinion+For+The+Orphan+Drug+Status+In+Europe titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&titleOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/&hOBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1308 post type-post status-publish format-standard hentry tag-congestive-heart-failure tag-diabetes tag-heart tag-heart-failure tag-hypertension tag-kidney-disease tag-pres tag-renal-disease tag-vascular-disease idpost-1308>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ relbookmark titlePermanent Link to Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease>Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>05/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease/span>/span>/p>			/div>			div classentry>				p>Databr />analyses from the largest initial registration clinical trial program everbr />undertaken in the renal anemia arena provide efficacy and safetybr />information on the investigational anemia therapy MIRCERA(TM) for thebr />treatment of renal anemia associated with chronic kidney disease (CKD) inbr />patients on dialysis and not on dialysis. Three data analyses werebr />presented at the National Kidney Foundation 2007 Spring Clinical Meetingsbr />in Orlando, Florida./p>p>According to these analyses, MIRCERA with extended dosing up to oncebr />every four weeks: (1) corrected and maintained hemoglobin (Hb) levels inbr />patients with CKD, on dialysis and not on dialysis; (2) maintained Hbbr />levels in dialysis patients, regardless of congestive heart failure (CHF)br />status as shown in a post-hoc analysis; and (3) exhibited a safety profilebr />that is consistent with that of commercially available erythropoiesisbr />stimulating agents (ESAs) and typical of those associated with this patientbr />population./p>p>“The goal in treating renal anemia is to safely maintain targetbr />hemoglobin levels,” said Steven Fishbane, MD, Associate Director ofbr />Nephrology, Associate Chairman of the Department of Medicine, and Directorbr />of End-Stage Renal Disease research at Winthrop University Hospital. “Thesebr />data analyses clearly demonstrate that MIRCERA corrected low hemoglobinbr />levels, and maintained target hemoglobin levels with the added conveniencebr />of up to once- monthly dosing.”/p>p>About the Studies/p>p>Safety and Tolerability of C.E.R.A. In Patients With Chronic Kidneybr />Disease: Pooled Data From Ten Phase II-III Trials/p>p>Pooled data from four Phase II and six Phase III studies evaluated thebr />safety and tolerability of MIRCERA (intravenous (IV) and subcutaneous (SC))br />in patients not previously treated with commercially available ESAs andbr />those previously treated with commercially available ESAs. This databr />analysis showed that the incidence of adverse events in the Phase II andbr />III safety population was similar between MIRCERA and reference groups, andbr />typical of those associated with this patient population; and thebr />administration of MIRCERA for the treatment of anemia associated with CKDbr />has a safety profile consistent with that of reference ESAs./p>p>C.E.R.A. Once Monthly Maintains Stable Hemoglobin Levels In Patientsbr />With Chronic Kidney Disease on Dialysis With and Without Congestive Heartbr />Failure (CHF)/p>p>This retrospective analysis of two Phase III studies evaluated thebr />efficacy and tolerability of MIRCERA (IV and SC) administered once everybr />two weeks or once every four weeks in patients with or without congestivebr />heart failure who were on dialysis and were directly converted from epoetinbr />alfa or beta. The post-hoc analysis showed that MIRCERA, administered atbr />extended dosing intervals, was effective in maintaining stable Hb levels inbr />dialysis patients with and without CHF who were directly switched frombr />shorter-acting ESAs./p>p>Efficacy of C.E.R.A. in Treatment of Renal Anemia: Overview of 6 Globalbr />Phase III Trials/p>p>This was an overview of six global studies in approximately 2,400br />patients that compared MIRCERA with epoetin alfa or beta and withbr />darbepoetin alfa. This overview showed that the efficacy of MIRCERA wasbr />comparable to that of the comparator agents, but required less frequentbr />administration./p>p>Chronic Kidney Disease and Renal Anemia/p>p>According to the National Kidney Foundation, 20 million Americans havebr />chronic kidney disease and another 20 million are at increased risk for thebr />condition. CKD is considered a rising global epidemic because it is linkedbr />to two of the fastest-growing diseases – diabetes and hypertension. Anbr />often under-diagnosed condition, CKD is called a disease multiplier becausebr />many of its risk factors are also complications of the disease itself,br />creating a relentless spiral in which one condition can lead to thebr />exacerbation of the other and, ultimately, to death. In particular, renalbr />anemia, diabetes and cardiovascular disease frequently play this doublebr />role./p>p>About MIRCERA/p>p>The initial registration clinical program for MIRCERA consisted of 10br />global studies involving more than 2,700 patients from 29 countries. Thebr />Phase III program for MIRCERA consisted of two correction and fourbr />maintenance studies exploring intravenous and subcutaneous MIRCERA atbr />extended administration intervals./p>p>Roche filed applications with the regulatory authorities in the Unitedbr />States and in the European Union in April 2006 seeking approval for the usebr />in the treatment of anemia associated with CKD in patients on dialysis andbr />not on dialysis./p>p>Safety Information/p>p>MIRCERA has a demonstrated safety profile comparable to otherbr />erythropoietic agents./p>p>The most commonly reported adverse events in the MIRCERA Phase II/IIIbr />clinical program were hypertension, nasopharyngitis and diarrhea.br />Erythropoietic therapies increase the risk of death and seriousbr />cardiovascular events when administered to a hemoglobin of greater than 12br />g/dL./p>p>Erythropoiesis stimulating agents, when administered to target abr />hemoglobin of greater than 12 g/dL have shortened the time to tumorbr />progression, shortened survival and increased the risk of death in cancerbr />patients./p>p>Pure Red Cell Aplasia (PRCA) has been observed in patients treated withbr />erythropoietin therapy. However, PRCA has not been observed with MIRCERA inbr />clinical trials to date./p>p>About Roche/p>p>Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S.br />pharmaceuticals headquarters of the Roche Group, one of the world’s leadingbr />research-oriented healthcare groups with core businesses in pharmaceuticalsbr />and diagnostics. For more than 100 years, the Roche Group has beenbr />committed to developing innovative products and services that addressbr />prevention, diagnosis and treatment of diseases, thus enhancing people’sbr />health and quality of life. An employer of choice, in 2006, Roche was namedbr />one of the Top 20 Employers (Science magazine), ranked the No. 1 Company tobr />Sell For (Selling Power), and one of AARP’s Top -Companies for Olderbr />Workers, and in 2005, Roche was named one of Fortune magazine’s Bestbr />Companies to Work For in America. For additional information about the U.S. pharmaceuticalsbr />business, visit our websites: rocheusa or roche.us./p>p>All trademarks used or mentioned in this release are protected by law./p>p>Rochebr />roche.us/p>p>View drug information on Mircera./p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/congestive-heart-failure/ reltag>Congestive heart failure/a>/li>li>a hrefhttp://bphmeds.net/tag/diabetes/ reltag>Diabetes/a>/li>li>a hrefhttp://bphmeds.net/tag/heart/ reltag>Heart/a>/li>li>a hrefhttp://bphmeds.net/tag/heart-failure/ reltag>Heart failure/a>/li>li>a hrefhttp://bphmeds.net/tag/hypertension/ reltag>Hypertension/a>/li>li>a hrefhttp://bphmeds.net/tag/kidney-disease/ reltag>Kidney disease/a>/li>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>li>a hrefhttp://bphmeds.net/tag/renal-disease/ reltag>Renal disease/a>/li>li>a hrefhttp://bphmeds.net/tag/vascular-disease/ reltag>Vascular disease/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&titleData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&titleData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&titleData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease+http://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&titleData+Analyses+Outline+Efficacy+And+Safety+Of+MIRCERA%28TM%29+For+The+Treatment+Of+Renal+Anemia+Associated+With+Chronic+Kidney+Disease titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&titleData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/&hData Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1306 post type-post status-publish format-standard hentry tag-bleeding tag-pres idpost-1306>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ relbookmark titlePermanent Link to Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007>Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>04/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007/span>/span>/p>			/div>			div classentry>				p>Pharmacogenomics offers the promise of individualized drug therapies based on a patient’s genetic make-up and that of the tumor cells. Such tailor-made drug regimes hold the promise to further increase survival rates for cancer. They could also decrease the sometimes lethal side effects of the powerful drugs used in cancer therapy, experts reported at the 12th Congress of the European Hematology Association in Vienna./p>p>The role of pharmacogenomics in the treatment of childhood acute lymphoblastic leukemia (ALL) was addressed today by Dr Leo Kager from St Anna Children’s Hospital in Vienna at the European Hematology Association congress in Vienna (Austria) from 7 to 10 June 2007. Pharmacogenomics is a new technique for investigating the influence of variations in genetic make-up on an individual’s response to a particular drug. Tests are carried out on patients’ blood or bone marrow cells to look at the expression of genes which affect drug metabolism and activity. These laboratory tests are then correlated with the actual response of patients to the same drugs both with respect to effectiveness and toxicty./p>p>Dr Kager says he has seen patients die because of toxic reactions to drugs used in leukemia treatments. In those patients where severe toxicity is exhibited, reactions can include such consequences as convulsions, severe infections or bleeding due to hemato-toxicity, liver failure, thrombosis, and mucositis./p>p>Toxic drug reactions are very individual. For example, 1 in 300 people may have a severe toxic reaction to a drug, while 10 percent of a sample of patients may exhibit low toxic reactions and 90% full tolerance of the same medication. “The great difficulty for physicians is that they must prescribe medication without being able to assess which patient will response with severe toxic reactions”, Dr Kager says./p>p>Genetic tests to prevent toxicity/p>p>Pharmacogenomics effectively means it may be possible to develop genetic tests that utilize a patient’s genetic profile to prevent toxicity. Simple as this may sound, Dr Kager says the difficulties should not be minimized: “Estimating appropriate drug dosages is a complicating factor. Administering too little of a drug can be dangerous, if poor results are achieved in the tumor cells targeted. What doctors need to know is what a particular drug will do in tumor cells.”/p>p>The latest research in pharmacogenomics examines the genetics of both normal and tumor cells, addressing the need to balance requirements to protect healthy tissue as much as possible while destroying the tumor./p>p>At the moment, ALL patients are stratified according to certain risk factors (e.g., age, cytogenetic changes in tumor cells, in vivo response to chemotherapy) to receive either very intensive treatment (so called ‘high-risk’ patients, which means based on their prognostic factors these patients have a high risk of relapse), or less intensive treatment (standard risk and low risk patients). Within a risk group all patients receive the same course of treatment of drugs, at the same dosage. It has been established empirically that these dosages represent the range of best available treatment. Dr Kager: “But this is clearly not the best for each individual patient, as is amply demonstrated by the fact that in patients with a high risk ALL, many patients survive, while in patients with a low risk ALL, a few patients die. The fact is that a patient may die because too low or too high dose of these very powerful drugs is administered.” In treating childhood ALL, a physician is normally working with a range of up to eight different drugs. Childhood ALL remains a rare disease, fortunately. But there is a slight increase in incidence./p>p>Promising approach to tailor therapy/p>p>Pharmacogenomics is of course relevant beyond the treatment of leukemia. Good success has already been achieved in the treatment of gastro-intestinal tumors. In fact these methods to assess drug effectiveness and toxicity begin to be applied in all fields. As a further example of the growing importance of pharmacogenomics, essential literature on hematology increasingly dedicates space to the field. In the use of oral anti-coagulants in treatment of thrombosis patients, which affects vastly more patients than leukemia, pharmacogenomics is a promising approach to tailor therapy./p>p>Front line research being conducted at the moment in pharmacogenomics has shown that cellular pathways targeted by antileukemic medications differ considerably in ALL subtypes. A powerful tool to analyze the expression of thousands of genes in one experiment are microarray gene chips. In such experiments, the expression of about 20,000 genes can be measured, and ground breaking work testing patients samples and cell lines is being done to ascertain the interplay between a drug and particular genes to understand better why some leukemia patients are resistant, for example, to cortisone treatment./p>p>Dr Kager: “While pharmacogenomics won’t perhaps explain all differences in individual patient reactions to drugs it can certainly further improve a physician’s ability to accurately prescribe.”/p>p>B&K KOMMUNIKATIONbr />Porzellangasse 35br />bkkommunikation.at/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/bleeding/ reltag>Bleeding/a>/li>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&titlePharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007 titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&titlePharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007 titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&titlePharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusPharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007+http://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&titlePharmacogenomics%3A+Decreasing+Drug+Toxicity+Through+Personalized+Medicine+EHA+Congress+2007 titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&titlePharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007 titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/&hPharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007 titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1304 post type-post status-publish format-standard hentry idpost-1304>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ relbookmark titlePermanent Link to During Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced>During Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>03/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on During Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced/span>/span>/p>			/div>			div classentry>				p>Doctors at Children’s National Medical Center have found that carbon monoxide levels in the blood of young children increase during routine general anesthesia. Anesthesiologists have found for the first time that, under certain circumstances, infants and children may be exposed to carbon monoxide during routine anesthesia resulting in a rise in the carbon monoxide levels in the child’s blood./p>p>Because carbon monoxide can be generated as a byproduct of anesthesia, anesthesiologists world-wide use specific precautions to prevent and limit its production, according to Richard J. Levy, MD, Chief of Cardiac Anesthesiology, at Children’s National. Dr. Levy’s team identified the conditions in which carbon monoxide may be inhaled during anesthesia:br />  The first study demonstrated that carbon monoxide detected in the breathing circuit correlated with the increase in blood levels in children 2 years and older. The study included 15 patients between 4 months and 8 years./p>p>  The second study identified that the patient’s own exhaled carbon monoxide may be “re-breathed” during low-flow anesthesia – the current standard of care – where fresh gas flows more slowly into the circuit, rather than rapidly./p>p>“The main goal is to provide the safest environment for young patients who require surgery,” said Dr. Levy. “We have identified tangible ways to reduce the risk of carbon monoxide exposure, and our hope is that these changes will be implemented internationally.”/p>p>Much remains unknown about the effects of low-dose carbon monoxide exposure on the developing brain. Several recent studies have suggested there may be a link to hearing impairments. Though there is more research to be done to determine these impacts, Dr. Levy recommends two immediate changes that will eliminate the risk of carbon monoxide exposure in children:br />  In the anesthesia machine, use carbon dioxide absorbents that lack strong metal alkali and do not degrade inhaled anesthetics (avoids CO production risk)/p>p>   Avoid of low-flow anesthesia (avoids CO re-breathing risk)/p>p>Following Dr. Levy’s study findings, Children’s National switched to the recommended absorbent to minimize the risk to patients. Although the sample size is small, the results are compelling and Dr. Levy believes changes should be implemented./p>p>Dr. Levy’s research has been named the top study out of 600 at the International Anesthesia Research Society 2010 meeting, and won the John J. Downes Research Award for best abstract at the upcoming Society of Pediatric Anesthesia/American Academy of Pediatrics 2010 Annual meeting./p>p>Source: br /> Emily Dammeyerbr />Children’s National Medical Center/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>							/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22During Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&titleDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&titleDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&titleDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced+http://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&titleDuring+Routine+Anesthesia+In+Kids%2C+Carbon+Monoxide+Exposure+Can+Be+Reduced titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&titleDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/&hDuring Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1302 post type-post status-publish format-standard hentry tag-pres idpost-1302>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ relbookmark titlePermanent Link to Chemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750>Chemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>02/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Chemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750/span>/span>/p>			/div>			div classentry>				p>Orcrist Bio Inc. (ORC) a biotech company developing stem cell-mobilizingbr />pharmaceuticals, announced today that it has filed with the Europeanbr />Competent Authority in Seville, Spain, a Phase I, open-label,br />single-ascending-dose, safety study of HYC750 in healthy male volunteers. Thebr />goal of the study is to assess the safety, tolerability, pharmacokinetics andbr />pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protectedbr />formulation of hyaluronan. ORC utilized the regulatory expertise andbr />experience of Kinesis Pharma BV (Breda, Netherlands) to develop the clinicalbr />trial submission. The planned study is to be conducted by InPEC BV (Breda,br />Netherlands) at their clinical trial site in Malaga, Spain. /p>p>    Dr. Thomas Ichim, Chairman of ORC’s Scientific Advisory Board commented,br />“HYC750 possesses a very favourable pharmacological and pharmaceuticalbr />profile and is an excellent candidate for aggressive and rapid clinicalbr />development.” /p>p>    “Filing the requisite regulatory documentation with the Europeanbr />authorities to initiate our Phase I clinical trial was a major accomplishmentbr />for our company and represents Orcrist’s most important milestone thus far,”br />said Dr. Brett SchÃ¶nekess, President and CEO of Orcrist. “We are thrilledbr />with the expertise and professionalism provided by both Kinesis and InPEC,br />and are very excited to see the HYC750 clinical program move forward. Ourbr />clinical goal is to confirm the safety profile of HYC750 and to see a clearbr />illustration of its stem cell mobilization properties, which would supportbr />its future development as a treatment for chemotherapy-related blood cellbr />depletion.” /p>p>    “We are very honored to be chosen by Orcrist to coordinate and performbr />their Phase I study with HYC750 and we look forward to the future initiationbr />of the trial,” commented Dr. Ronald van der Geest, Chief Business Officer ofbr />InPEC BV. “Orcrist, Kinesis, and InPEC have worked as a team on this project,br />and I believe a very strong clinical trial application has been submitted.” /p>p>   About Orcrist Bio Inc. /p>p>    Orcrist Bio Inc. is a biotechnology company dedicated to developing andbr />commercializing promising therapeutics for areas in which a clear marketbr />opportunity exists. ORC’s lead program revolves around HYC750, a novel stembr />cell mobilizer compound that promotes the egress of stem cells and otherbr />blood cells from the bone marrow into the blood, from which they can bebr />harvested and applied toward treating chemotherapy-related white blood cellbr />depletion. Orcrist is actively looking to add to its pipeline exploring thebr />innate properties of HYC750 and its effects on stem cells, as well as throughbr />in-licensing opportunities of other products with clear market potential. ORCbr />is located in Calgary, Alberta. The company is financed by its founders andbr />by private investors. /p>p>    About Kinesis Pharma BV/p>p>    Kinesis Pharma BV is an independent, privately owned company based in Thebr />Netherlands. Kinesis aims to facilitate a fast and high quality drugbr />development process in close collaboration with the preclinical and clinicalbr />R&D departments of pharmaceutical and biotech companies through consultancybr />and contract research services. Currently, Kinesis employs about 55 people,br />many of them with extensive industrial and/or regulatory experience. /p>p>    About InPEC BV/p>p>    InPEC BV is a clinical CRO that focuses on the execution of Phase I andbr />IIa clinical trials. Its professional and experienced team, and state of thebr />art facilities, embedded within the care of a private hospital with an ICUbr />unit on the same floor, guarantee maximum safety for the full range ofbr />clinical pharmacology studies. Electronic data processing procedures are inbr />place to enable high-quality and efficient data processing on-site. InPEC’sbr />head office is located in the Netherlands. Clinical facilities are located inbr />Malaga, Spain. /p>p>Orcrist Bio Inc./p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Chemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&titleChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750 titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&titleChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750 titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&titleChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750+http://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&titleChemotherapy-related+White+Blood+Cell+Depletion+%26%238211%3B+Application+For+Phase+I%2C+Open-Label%2C+Single-Ascending-Dose%2C+Safety+Study+Of+HYC750 titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&titleChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750 titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/&hChemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750 titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1300 post type-post status-publish format-standard hentry tag-istin tag-pres idpost-1300>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ relbookmark titlePermanent Link to Research Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia>Research Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia/a>/h3>				div classpostDate>					span classmonth>11/span>					span classday>01/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Research Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia/span>/span>/p>			/div>			div classentry>				p>Virginia Commonwealth University researchers studying hemoglobin genes, mutations of which play a role in genetic blood disorders like sickle cell anemia and beta-thalassemia, have identified two proteins that are responsible for regulating overlapping groups of genes during the development of red blood cells./p>p>The findings may point researchers to future gene therapies for patients with sickle cell anemia and beta-thalassemia./p>p>In an article pre-published online as a First Edition Paper in the journal Blood, the journal of the American Association for Hematology, researchers reported that a protein called KLF2 coordinates with a related and well-studied transcription factor, EKLF, in the regulation of embryonic globin genes responsible for the development of mouse embryonic red blood cells./p>p>EKLF plays a central role in the developmental regulation of the adult beta-globin gene, and is essential for the maturation and stability of adult red blood cells. KLF2 is a protein crucial for making embryonic red blood cells./p>p>“If EKLF and KLF2 can turn on the embryonic globin genes in adult cells — we don’t know if this is true yet — then these findings may provide a gene therapy approach for treating sickle cell anemia and beta-thalassemia. It is well-established that the expression of embryonic globin genes can help ameliorate these diseases,” said Joyce A. Lloyd, Ph.D., associate professor of human genetics at the VCU Massey Cancer Center, and corresponding author for this study./p>p>Lloyd’s team studied gene expression and red blood cell development in the mouse embryo. They used mouse embryos missing both the KLF2 and EKLF genes to show that embryonic globin expression is severely reduced, and that the embryos therefore are anemic, compared to mice missing KLF2 or EKLF alone./p>p>“This likely means that EKLF and KLF2, which are related transcription factors, regulate overlapping groups of genes in developing red blood cells. In the absence of both factors, they cannot compensate for each other, causing more serious defects in red blood cell development,” Lloyd said./p>p>According to Lloyd, the production of blood cells involves a complex differentiation pathway with interactions between many molecular players and proteins./p>p>In humans, there are four globin genes clustered on chromosome 11 in the order in which they are ‘turned on’ or expressed. These genes include the epsilon-globin gene, two gamma-globin genes and the beta-globin gene. Lloyd said that during fetal development, the embryonic epsilon-globin gene is active first, followed by the gamma-globin genes, and finally the adult form, beta-globin takes control following birth./p>p>Understanding how genes are regulated or turned on and off is critical. In gene therapy, a normal gene can be inserted into cells to correct a genetic defect. However, according to Lloyd, in this case, the goal would be to insert a transcription factor into adult cells that would turn on an existing, silenced embryonic gene./p>p>This research was supported by a grant from the National Institutes of Health./p>p>Lloyd collaborated with Jack Haar, Ph.D., professor of anatomy and neurobiology in the VCU School of Medicine; Priyadarshi Basu, Ph.D., a former postdoctoral fellow at VCU; and Tina Lung, who recently earned her masters degree. Additionally, colleagues from the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati also contributed to this work./p>p>About VCU and the VCU Medical Center: Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificate and degree programs in the arts, sciences and humanities. Sixty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see vcu/./p>p>About the VCU Massey Cancer Center: The VCU Massey Cancer Center is one of 61 National Cancer Institute-designated institutions that leads and shapes America’s cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at massey.vcu/./p>p>Source: Sathya Achia-Abrahambr />br />Virginia Commonwealth University/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/istin/ reltag>Istin/a>/li>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Research Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&titleResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&titleResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&titleResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia+http://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&titleResearch+Could+Lead+To+Gene+Therapy+Approach+For+Treating+Sickle+Cell+Anemia+And+Beta-Thalassemia titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&titleResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/&hResearch Could Lead To Gene Therapy Approach For Treating Sickle Cell Anemia And Beta-Thalassemia titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/research-could-lead-to-gene-therapy-approach-for-treating-sickle-cell-anemia-and-beta-thalassemia/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1298 post type-post status-publish format-standard hentry tag-bleeding tag-hemophilia idpost-1298>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ relbookmark titlePermanent Link to Commentary: Why We Need Better Drug Monitoring>Commentary: Why We Need Better Drug Monitoring/a>/h3>				div classpostDate>					span classmonth>10/span>					span classday>31/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Commentary: Why We Need Better Drug Monitoring/span>/span>/p>			/div>			div classentry>				p>The use of recombinant activated factor 7 (rFVIIa) despite its potential for adverse events displays the serious shortcomings of Canada’s current drug surveillance system, according to a commentary published in  CMAJ (Canadian Medical Association Journal) ./p>p>Off-label use of this therapy – a blood product – was driven by key physician opinion leaders who thought recombinant factor VIIa could be used to treat or prevent bleeding in patients without hemophilia at risk of death. This shows how promising case reports can change practice prematurely before more data is available./p>p>Use of recombinant factor VIIa in patients without hemophilia is expensive, marginally effective and risky./p>p> “Off-label use of drugs can be beneficial, however, without a process for ongoing evaluation, deaths, disabilities and costs may be accruing without being obvious at the bedside,” writes Paul HÃ©bert, Editor-in-Chief, CMAJ, with coauthors. “With recombinant factor VIIa, physicians were too eager to believe the anecdotes and did not push for the appropriate studies.”/p>p>Monitoring drug use as well as safety is complicated and lacks a simple solution, although several changes should be considered. These include improved collaboration between payers and insurers who approve and track usage as well as manufacturers, prioritizing higher risk drugs in an improved drug surveillance system, better evaluation of new drugs and greater surveillance powers for regulatory bodies. /p>p>Source: CMAJ (Canadian Medical Association Journal)/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/bleeding/ reltag>Bleeding/a>/li>li>a hrefhttp://bphmeds.net/tag/hemophilia/ reltag>Hemophilia/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Commentary: Why We Need Better Drug Monitoring%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&titleCommentary: Why We Need Better Drug Monitoring titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&titleCommentary: Why We Need Better Drug Monitoring titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&titleCommentary: Why We Need Better Drug Monitoring&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusCommentary: Why We Need Better Drug Monitoring+http://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&titleCommentary%3A+Why+We+Need+Better+Drug+Monitoring titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&titleCommentary: Why We Need Better Drug Monitoring titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/&hCommentary: Why We Need Better Drug Monitoring titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/commentary-why-we-need-better-drug-monitoring/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1296 post type-post status-publish format-standard hentry tag-istin tag-pres idpost-1296>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ relbookmark titlePermanent Link to New Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance>New Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance/a>/h3>				div classpostDate>					span classmonth>10/span>					span classday>30/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on New Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance/span>/span>/p>			/div>			div classentry>				p>The development of the targetedbr />anticancer medicine imatinib has been a landmark event in the treatment ofbr />patients with chronic myeloid leukemia (CML), a cancer of the bone marrow.br />However, over time, the cancer can become resistant to this treatment,br />usually because of mutations in the protein that imatinib targets. Twobr />studies being presented today at the 48th Annual Meeting of the Americanbr />Society of Hematology (ASH(TM)) highlight new compounds in development thatbr />can effectively treat CML when imatinib is no longer effective./p>p>“This is important progress for patients who relapse on imatinibbr />therapy,” said Charles A. Linker, MD, University of California, Sanbr />Francisco. “Not only does this research show the efficacy of new treatmentsbr />for imatinib- resistant disease, it also demonstrates the value of lookingbr />at each patient’s mutation pattern to determine an individual course ofbr />therapy.”/p>p>Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN 107)br />Depend on the Type of BCR-ABL Mutations in Patients with Chronicbr />Myelogenous Leukemia (CML) after Imatinib Failure Abstract #749/p>p>Treatment with imatinib has allowed patients with chronic myelogenousbr />leukemia (CML) to experience a nearly 90 percent five-year survival rate,br />as the drug blocks the tyrosine kinase BCR-ABL, an abnormal protein drivingbr />the overproduction of abnormal white blood cells characteristic ofbr />leukemia. However, many patients have eventually developed resistance tobr />this treatment because their cancer cells are able to mutate and adapt,br />causing their disease to relapse./p>p>Researchers studied nilotinib, a novel treatment that blocks thebr />BCR-ABL protein, to determine its effectiveness among patients for whombr />imatinib has stopped working. In vitro work showed effectiveness even inbr />patients developing BCR-ABL mutations associated with resistance tobr />imatinib. Investigators looked at blood samples from 101 CML patients, 64br />of whom were in the early or chronic phase, 22 in the later or acceleratedbr />phase, and 15 in the final or blast crisis phase of the disease, andbr />screened for the BCR-ABL gene mutation that signals CML./p>p>Prior to treatment with nilotinib, researchers found 28 differentbr />BCR-ABL mutations in 61 patients. Of this group, nine showed two mutations,br />three showed three mutations, and one patient showed four mutations. Whenbr />treated with nilotinib twice a day (400 mg), 70 percent of patients withbr />mutations experienced a hematologic response, with the highest rate ofbr />response seen in patients in the chronic phase (78 percent), followed bybr />accelerated phase (75 percent) and blast crisis (25 percent). Patientsbr />without mutations responded even better to the therapy, as 88 percentbr />experienced a hematologic response rate./p>p>Chronic phase patients whose genetic mutations had shown sensitivity tobr />nilotinib in the lab achieved a complete cytogenetic response within threebr />to six months. Two patients with the BCR-ABL mutation T315I — a mutationbr />highly resistant to both imatinib and nilotinib in the lab — showed nobr />signs of relapse of disease after one month and 11 months of treatment withbr />nilotinib, respectively./p>p>“This preliminary data suggests that nilotinib may help patients forbr />whom imatinib has stopped working by overcoming the gene mutations thatbr />cause imatinib resistance,” said Andreas Hochhaus, MD, of the Medicalbr />Faculty Mannheim of the University of Heidelberg, Germany. “It also showsbr />the importance of determining each patient’s specific gene mutation, tobr />apply individualized dosage of nilotinib according to the mutationbr />pattern.”/p>p>Response to Dasatinib after Imatinib Failure According to Type ofbr />Preexisting BCR-ABL Mutations Abstract #748/p>p>Dasatinib blocks the production of BCR-ABL and it has been shown tobr />treat CML and ALL that have become resistant to the standard therapy ofbr />imatinib./p>p>This study looked at the type of gene mutations that are morebr />responsive to treatment with dasatinib to confirm the best targets forbr />future therapy. Blood samples from 394 patients being treated withbr />dasatinib (198 chronic phase, 78 accelerated phase, 53 myeloid blastbr />crisis, and 65 lymphoid blast crisis/ALL) were monitored in three monthbr />intervals to determine how the preexisting genetic mutations responded tobr />the therapy and if new mutations emerged. Prior to treatment, 46 differentbr />BCR-ABL mutations were detected in 202 patients — 162 patients showed one,br />33 patients showed two, six patients showed three, and one patient showedbr />four mutations./p>p>Patients with mutations responded well to therapy, as completebr />hematologic response was achieved in 91 percent of chronic phase patients,br />62 percent of accelerated phase patients, 41 percent of myeloid blastbr />crisis patients, and 34 percent of lymphoid blast crisis/ALL patients.br />Complete cytogenetic responses were similar and occurred in 37 percent ofbr />chronic phase patients, 27 percent of accelerated phase patients, 28br />percent of myeloid blast crisis patients, and 51 percent of lymphoid blastbr />crisis patients./p>p>Researchers observed two response patterns in studying treatment withbr />dasatinib: some patients experienced a decrease in the BCR-ABL expressionbr />and the proportion of the mutated clone simultaneously, while othersbr />experienced a decrease in BCR-ABL followed by a decrease of the mutatedbr />clone after a delay of four to six months. Five patients developed newbr />mutations associated with resistance to dasatinib, including T315I. Thebr />T315I mutation is highly resistant to both imatinib and dasatinib./p>p>“Dasatinib is an excellent treatment option for patients who havebr />become resistant to imatinib,” said lead researcher, Martin C. Muller, MD,br />Medical Faculty Mannheim of the University of Heidelberg, Germany.br />“However, we noted that response depended heavily on the type of geneticbr />mutation, which may signal a method for individualizing each patient’sbr />dose.”/p>p>The American Society of Hematology (hematology) is thebr />world’s largest professional society concerned with the causes andbr />treatment of blood disorders. Its mission is to further the understanding,br />diagnosis, treatment, and prevention of disorders affecting blood, bonebr />marrow, and the immunologic, hemostatic, and vascular systems, by promotingbr />research, clinical care, education, training, and advocacy in hematology./p>p>American Society of Hematologybr />hematology/p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/istin/ reltag>Istin/a>/li>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22New Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&titleNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&titleNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&titleNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance+http://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&titleNew+Options+To+Treat+Chronic+Myeloid+Leukemia%2C+Overcome+Imatinib+Resistance titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&titleNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/&hNew Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/new-options-to-treat-chronic-myeloid-leukemia-overcome-imatinib-resistance/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1294 post type-post status-publish format-standard hentry idpost-1294>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ relbookmark titlePermanent Link to Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC>Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC/a>/h3>				div classpostDate>					span classmonth>10/span>					span classday>29/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC/span>/span>/p>			/div>			div classentry>				p>Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® – recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC. The clinical study enrolled 750 patients in over 150 sites worldwide. /p>p> “DIC in sepsis is a severe condition with a very poor prognosis for patients,” stated Dr. Inder Kaul, M.D., M.P.H., Chief Medical Officer of Artisan Pharma. “We are energized at having reached this milestone and now will be focusing on preparing to analyze the results, which are highly anticipated by the medical and scientific communities.” /p>p>“We are very pleased to have achieved this important milestone for Artisan and expect to report the results later this year,” commented Dr. Gary T. Shearman, Executive Chairman. /p>p>About ART-123 /p>p>ART-123 is a novel, recombinant, soluble thrombomodulin for the treatment of DIC (disseminated intravascular coagulation) in sepsis. ART-123 uniquely targets both anti-coagulant and systemic anti-inflammatory pathways, and holds great promise as a self-regulating treatment of DIC in sepsis. Artisan licensed ART-123 from Asahi Kasei Pharma Corporation and holds all development and commercial rights for ART-123 outside of Japan, China, Taiwan and Korea. ART-123 is approved for marketing in Japan for the treatment of DIC. /p>p>About DIC in Sepsis /p>p>Almost 2 million patients in the United States and Europe suffer from sepsis annually, with up to 30% of them developing or being at high risk of developing DIC. For those that do, prognosis is poor. DIC is a severe condition in which widespread microthrombi formation ultimately contributes to organ dysfunction and death. This market is estimated at over $2 billion and is increasing due to the growing incidence of sepsis in the industrialized world. /p>p>Sourcebr />Artisan Pharma, Inc./p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>							/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&titleArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&titleArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&titleArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC+http://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&titleArtisan+Pharma%2C+Inc.+Completes+Enrollment+In+750-patient+Phase+2b+Study+Of+ART-123+In+Sepsis+Patients+With+DIC titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&titleArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/&hArtisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/artisan-pharma-inc-completes-enrollment-in-750-patient-phase-2b-study-of-art-123-in-sepsis-patients-with-dic/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>				div classpost-1292 post type-post status-publish format-standard hentry tag-pres idpost-1292>			div classmainTitle>				h3>a hrefhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ relbookmark titlePermanent Link to CaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology>CaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology/a>/h3>				div classpostDate>					span classmonth>10/span>					span classday>28/span>					span classyear>15/span>				/div>			/div>						div classpostMeta postAuthorAndComments>				p classauthor>Written by strong>admin/strong>/p>				p classcommentNumber>span>Comments Offspan classscreen-reader-text> on CaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology/span>/span>/p>			/div>			div classentry>				p>CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies, announced today it has signed a multi-year agreement with the American Red Cross to continue the use of its automated blood collection technology in American Red Cross Blood centers throughout the United States. /p>p>For over 50 years, the American Red Cross has been a primary supplier of life-saving blood and blood products in the U.S. Through its Biomedical Services division, the American Red Cross collects and distributes nearly half of the U.S. blood supply, collecting over 6 million units of blood from nearly 4 million blood donors annually. /p>p>“The relationship between the American Red Cross and CaridianBCT is reflective of our combined passion to meet the ever-increasing patient needs for safe, critical blood components,” said American Red Cross Biomedical Services Executive Vice President J. Chris Hrouda. “Under this agreement, we will continue to use CaridianBCT’s Trima Accel® system for the greater collection flexibility.” /p>p>The increasing demand for blood components and testing standards, as well as the decreasing donor availability, has heightened the need for blood centers to maximize the ability of every eligible donor to donate the specific blood components required to meet patient needs – a critical factor in ensuring a sufficient, safe blood supply. The Trima Accel system enables blood centers to collect multiple component combinations of leukoreduced, ready-to-store red cells – including double red cells – platelets and plasma, from a single donor, in a single donation. /p>p>“We have been extremely pleased with the close working relationship between CaridianBCT and the American Red Cross,” said CaridianBCT President and Chief Executive Officer David B. Perez. “Together, we strive to enhance the productivity capabilities of our Trima technology to collect more of the right blood components, exactly when they are needed to better serve patients, who are the ultimate beneficiaries of the life-saving gift of blood. Our people, products and processes are very much aligned with the goals and objectives of the American Red Cross and the working relationship we have with the American Red Cross allows us to live out our vision, For Better Blood and Better Lives, every day.” /p>p>About CaridianBCT:/p>p>CaridianBCT, Inc. improves lives through innovation, quality and services delivered by its people, products and processes in blood component technology. It is a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies – serving blood banks, hospitals and clinical and biotech research facilities. Headquartered in Lakewood, CO, the company has global operations in 32 countries and employs approximately 2500 people. For more information, visit caridianbct. /p>p>About the American Red Cross:/p>p>The American Red Cross shelters, feeds and counsels victims of disasters; provides nearly half of the nation’s blood supply; teaches lifesaving skills; and supports military members and their families. The Red Cross is a charitable organization – not a government agency – and depends on volunteers and the generosity of the American public to perform its humanitarian mission. For more information, please visit redcross or join our blog at redcrosschat./p>			/div>			div classpostMeta postCategory>				p classpostCategory-title>strong>Category:/strong>/p>				p classpostCategory-elements>Uncategorized/p>			/div>			div classpostMeta postTags>				p>strong>Tagged with:/strong>/p>				ul>li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>/ul>			/div>			div classpostMeta postShare>				p>strong>Share it:/strong>/p>				ul>					li classshare-Email>a relnofollow hrefmailto:?subjectAn%20interesting%20post%20on%Buy Blood Pressure/Heart Drugs without Prescription&bodyCheck%20out%20%22CaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology%22%20from%20Buy Blood Pressure/Heart Drugs without Prescription: http://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleSend a link to this post by email>Share this post by E-mail/a>/li>					li classshare-Delicious>a relnofollow hrefhttp://del.icio.us/post?urlhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&titleCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology titleBookmark this post on Delicious target_blank>Share this post on Delicious/a>/li>					li classshare-Digg>a relnofollow hrefhttp://digg.com/submit?phase2&urlhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&titleCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology titleShare this post on Digg target_blank>Share this post on Digg/a>/li>					li classshare-Facebook>a relnofollow hrefhttp://www.facebook.com/share.php?uhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleShare this post on Facebook target_blank>Share this post on Facebook/a>/li>					li classshare-Myspace>a relnofollow hrefhttp://www.myspace.com/Modules/PostTo/Pages/?l3&uhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleShare this post on Mysace target_blank>Share this post on Myspace/a>/li>					li classshare-Google>a relnofollow hrefhttp://www.google.co.uk/bookmarks/mark?opedit&bkmkhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleBookmark this post on Google target_blank>Share this post on Google/a>/li>					li classshare-Linkedin>a relnofollow hrefhttp://www.linkedin.com/shareArticle?minitrue&urlhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&titleCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology&summary&sourceBuy Blood Pressure/Heart Drugs without Prescription>Share this post on LinkedIn/a>/li>					li classshare-Twitter>a relnofollow hrefhttp://twitter.com/home?statusCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology+http://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleShare this post on Twitter target_blank>Share this post on Twitter/a>/li>					li classshare-Reddit>a relnofollow hrefhttp://reddit.com/submit?urlhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&titleCaridianBCT+And+American+Red+Cross+Sign+Strategic+Agreement+On+Automated+Blood+Collection+Technology titleShare this post on Reddit target_blank>Share this post on Reddit/a>/li>					li classshare-Stumbleupon>a relnofollow hrefhttp://www.stumbleupon.com/submit?urlhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&titleCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology titleShare this post on Stumbleupon target_blank>Share this post on Stumbleupon/a>/li>					li classshare-Newsvine>a relnofollow hrefhttp://www.newsvine.com/_tools/seed&save?uhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/&hCaridianBCT And American Red Cross Sign Strategic Agreement On Automated Blood Collection Technology titleShare this post on Newsvine target_blank>Share this post on Newsvine/a>/li>					li classshare-Technoratti>a relnofollow hrefhttp://technorati.com/faves?addhttp://bphmeds.net/caridianbct-and-american-red-cross-sign-strategic-agreement-on-automated-blood-collection-technology/ titleShare this post on Technorati target_blank>Share this post on Technorati/a>/li>				/ul>			/div>		/div>			/div>	div idsidebar>		div classsidebarBox idsearchBox>			div classsidebarTitle>				h4>Search/h4>			/div>			form methodget idsearchform actionhttp://bphmeds.net/ >	p>		label fors classaccesible>Search:/label>		input typetext value names ids />		button typesubmit>Go!/button>	/p>/form>		/div>		div classsidebarBox idcategoryBox>			div classsidebarTitle>				h4>Categories/h4>			/div>			ul>				li classcat-item-none>No categories/li>			/ul>		/div>		div classsidebarBox idrecentPostsBox>			div classsidebarTitle>				h4>Recent Posts/h4>			/div>			ul>					li>a hrefhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/>OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe/a>/li>	li>a hrefhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/>Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease/a>/li>	li>a hrefhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/>Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007/a>/li>			/ul>		/div>		div classsidebarBox idrecentCommentsBox>			div classsidebarTitle>				h4>Recent Comments/h4>			/div>			ul>							/ul>		/div>			div classsidebarBox idarchivesBox>			div classsidebarTitle>				h4>Archives/h4>			/div>			ul>					li>a hrefhttp://bphmeds.net/2015/11/>November 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/10/>October 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/09/>September 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/08/>August 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/07/>July 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/06/>June 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/05/>May 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/04/>April 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/03/>March 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/02/>February 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/01/>January 2015/a>/li>	li>a hrefhttp://bphmeds.net/2014/12/>December 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/11/>November 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/10/>October 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/09/>September 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/08/>August 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/07/>July 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/06/>June 2014/a>/li>			/ul>		/div>		div classsidebarBox idblogrollBox>			div classsidebarTitle>				h4>Blogroll/h4>			/div>			ul>							/ul>		/div>		div idwidgetList>			div classsidebarBox>form methodget idsearchform actionhttp://bphmeds.net/ >	p>		label fors classaccesible>Search:/label>		input typetext value names ids />		button typesubmit>Go!/button>	/p>/form>/div>		div classsidebarBox>		div classsidebarTitle>h4>Recent Posts/h4>/div>		ul>					li>				a hrefhttp://bphmeds.net/obi-1-developed-by-ipsen-and-inspiration-has-obtained-a-positive-opinion-for-the-orphan-drug-status-in-europe/>OBI-1 Developed By Ipsen And Inspiration Has Obtained A Positive Opinion For The Orphan Drug Status In Europe/a>						/li>					li>				a hrefhttp://bphmeds.net/data-analyses-outline-efficacy-and-safety-of-mirceratm-for-the-treatment-of-renal-anemia-associated-with-chronic-kidney-disease/>Data Analyses Outline Efficacy And Safety Of MIRCERA(TM) For The Treatment Of Renal Anemia Associated With Chronic Kidney Disease/a>						/li>					li>				a hrefhttp://bphmeds.net/pharmacogenomics-decreasing-drug-toxicity-through-personalized-medicine-eha-congress-2007/>Pharmacogenomics: Decreasing Drug Toxicity Through Personalized Medicine EHA Congress 2007/a>						/li>					li>				a hrefhttp://bphmeds.net/during-routine-anesthesia-in-kids-carbon-monoxide-exposure-can-be-reduced/>During Routine Anesthesia In Kids, Carbon Monoxide Exposure Can Be Reduced/a>						/li>					li>				a hrefhttp://bphmeds.net/chemotherapy-related-white-blood-cell-depletion-application-for-phase-i-open-label-single-ascending-dose-safety-study-of-hyc750/>Chemotherapy-related White Blood Cell Depletion – Application For Phase I, Open-Label, Single-Ascending-Dose, Safety Study Of HYC750/a>						/li>				/ul>		/div>		div classsidebarBox>div classsidebarTitle>h4>Archives/h4>/div>		ul>			li>a hrefhttp://bphmeds.net/2015/11/>November 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/10/>October 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/09/>September 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/08/>August 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/07/>July 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/06/>June 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/05/>May 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/04/>April 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/03/>March 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/02/>February 2015/a>/li>	li>a hrefhttp://bphmeds.net/2015/01/>January 2015/a>/li>	li>a hrefhttp://bphmeds.net/2014/12/>December 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/11/>November 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/10/>October 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/09/>September 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/08/>August 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/07/>July 2014/a>/li>	li>a hrefhttp://bphmeds.net/2014/06/>June 2014/a>/li>		/ul>		/div>		/div>	/div>div idnavigation>	p idprevPage>a hrefhttp://bphmeds.net/page/2/ >Previous Posts/a>/p>	p idnextPage>/p>/div>			div idtagCloud>				div classsubTitle>					h4>strong>Tag Cloud/strong>/h4>				/div>				ul>											li>a hrefhttp://bphmeds.net/tag/pres/ reltag>Pres/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypertension/ reltag>Hypertension/a>/li>											li>a hrefhttp://bphmeds.net/tag/high-blood-pressure/ reltag>High blood pressure/a>/li>											li>a hrefhttp://bphmeds.net/tag/heart/ reltag>Heart/a>/li>											li>a hrefhttp://bphmeds.net/tag/iscover/ reltag>Iscover/a>/li>											li>a hrefhttp://bphmeds.net/tag/bleeding/ reltag>Bleeding/a>/li>											li>a hrefhttp://bphmeds.net/tag/istin/ reltag>Istin/a>/li>											li>a hrefhttp://bphmeds.net/tag/myocardial-infarction/ reltag>Myocardial infarction/a>/li>											li>a hrefhttp://bphmeds.net/tag/stroke/ reltag>Stroke/a>/li>											li>a hrefhttp://bphmeds.net/tag/heart-failure/ reltag>Heart failure/a>/li>											li>a hrefhttp://bphmeds.net/tag/angina-pectoris/ reltag>Angina pectoris/a>/li>											li>a hrefhttp://bphmeds.net/tag/congestive-heart-failure/ reltag>Congestive heart failure/a>/li>											li>a hrefhttp://bphmeds.net/tag/edema/ reltag>Edema/a>/li>											li>a hrefhttp://bphmeds.net/tag/kidney-disease/ reltag>Kidney disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/angina/ reltag>Angina/a>/li>											li>a hrefhttp://bphmeds.net/tag/diabetes/ reltag>Diabetes/a>/li>											li>a hrefhttp://bphmeds.net/tag/heart-attack/ reltag>Heart attack/a>/li>											li>a hrefhttp://bphmeds.net/tag/diuretic/ reltag>Diuretic/a>/li>											li>a hrefhttp://bphmeds.net/tag/arrhythmia/ reltag>Arrhythmia/a>/li>											li>a hrefhttp://bphmeds.net/tag/vascular-disease/ reltag>Vascular disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypoten/ reltag>Hypoten/a>/li>											li>a hrefhttp://bphmeds.net/tag/atrial-fibrillation/ reltag>Atrial fibrillation/a>/li>											li>a hrefhttp://bphmeds.net/tag/tenormin/ reltag>Tenormin/a>/li>											li>a hrefhttp://bphmeds.net/tag/atenolol/ reltag>Atenolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/hydrochlorothiazide/ reltag>Hydrochlorothiazide/a>/li>											li>a hrefhttp://bphmeds.net/tag/high-cholesterol/ reltag>High cholesterol/a>/li>											li>a hrefhttp://bphmeds.net/tag/aldactazide/ reltag>Aldactazide/a>/li>											li>a hrefhttp://bphmeds.net/tag/blood-pressure/ reltag>Blood pressure/a>/li>											li>a hrefhttp://bphmeds.net/tag/hemophilia/ reltag>Hemophilia/a>/li>											li>a hrefhttp://bphmeds.net/tag/amlodipine/ reltag>Amlodipine/a>/li>											li>a hrefhttp://bphmeds.net/tag/antipressan/ reltag>Antipressan/a>/li>											li>a hrefhttp://bphmeds.net/tag/atenix/ reltag>Atenix/a>/li>											li>a hrefhttp://bphmeds.net/tag/atelol/ reltag>Atelol/a>/li>											li>a hrefhttp://bphmeds.net/tag/atendol/ reltag>Atendol/a>/li>											li>a hrefhttp://bphmeds.net/tag/ateno/ reltag>Ateno/a>/li>											li>a hrefhttp://bphmeds.net/tag/atenogamma/ reltag>Atenogamma/a>/li>											li>a hrefhttp://bphmeds.net/tag/atereal/ reltag>Atereal/a>/li>											li>a hrefhttp://bphmeds.net/tag/betacard/ reltag>Betacard/a>/li>											li>a hrefhttp://bphmeds.net/tag/blokium/ reltag>Blokium/a>/li>											li>a hrefhttp://bphmeds.net/tag/catenol/ reltag>Catenol/a>/li>											li>a hrefhttp://bphmeds.net/tag/corotenol/ reltag>Corotenol/a>/li>											li>a hrefhttp://bphmeds.net/tag/cuxanorm/ reltag>Cuxanorm/a>/li>											li>a hrefhttp://bphmeds.net/tag/noten/ reltag>Noten/a>/li>											li>a hrefhttp://bphmeds.net/tag/notenol/ reltag>Notenol/a>/li>											li>a hrefhttp://bphmeds.net/tag/paesumex/ reltag>Paesumex/a>/li>											li>a hrefhttp://bphmeds.net/tag/tenolol/ reltag>Tenolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/tenopress/ reltag>Tenopress/a>/li>											li>a hrefhttp://bphmeds.net/tag/tredol/ reltag>Tredol/a>/li>											li>a hrefhttp://bphmeds.net/tag/hipres/ reltag>Hipres/a>/li>											li>a hrefhttp://bphmeds.net/tag/left-ventricular-dysfunction/ reltag>Left ventricular dysfunction/a>/li>											li>a hrefhttp://bphmeds.net/tag/vasotec/ reltag>Vasotec/a>/li>											li>a hrefhttp://bphmeds.net/tag/enalapril/ reltag>Enalapril/a>/li>											li>a hrefhttp://bphmeds.net/tag/xanef/ reltag>Xanef/a>/li>											li>a hrefhttp://bphmeds.net/tag/renitec/ reltag>Renitec/a>/li>											li>a hrefhttp://bphmeds.net/tag/nuril/ reltag>Nuril/a>/li>											li>a hrefhttp://bphmeds.net/tag/invoril/ reltag>Invoril/a>/li>											li>a hrefhttp://bphmeds.net/tag/innovace/ reltag>Innovace/a>/li>											li>a hrefhttp://bphmeds.net/tag/glioten/ reltag>Glioten/a>/li>											li>a hrefhttp://bphmeds.net/tag/envas/ reltag>Envas/a>/li>											li>a hrefhttp://bphmeds.net/tag/enatec/ reltag>Enatec/a>/li>											li>a hrefhttp://bphmeds.net/tag/enap/ reltag>Enap/a>/li>											li>a hrefhttp://bphmeds.net/tag/enalagamma/ reltag>Enalagamma/a>/li>											li>a hrefhttp://bphmeds.net/tag/ednyt/ reltag>Ednyt/a>/li>											li>a hrefhttp://bphmeds.net/tag/ecaprinil/ reltag>Ecaprinil/a>/li>											li>a hrefhttp://bphmeds.net/tag/corvo/ reltag>Corvo/a>/li>											li>a hrefhttp://bphmeds.net/tag/converten/ reltag>Converten/a>/li>											li>a hrefhttp://bphmeds.net/tag/bql/ reltag>Bql/a>/li>											li>a hrefhttp://bphmeds.net/tag/benalipril/ reltag>Benalipril/a>/li>											li>a hrefhttp://bphmeds.net/tag/auspril/ reltag>Auspril/a>/li>											li>a hrefhttp://bphmeds.net/tag/amprace/ reltag>Amprace/a>/li>											li>a hrefhttp://bphmeds.net/tag/alphapril/ reltag>Alphapril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hemorrhage/ reltag>Hemorrhage/a>/li>											li>a hrefhttp://bphmeds.net/tag/cholesterol/ reltag>Cholesterol/a>/li>											li>a hrefhttp://bphmeds.net/tag/water-retention/ reltag>Water retention/a>/li>											li>a hrefhttp://bphmeds.net/tag/hct/ reltag>Hct/a>/li>											li>a hrefhttp://bphmeds.net/tag/acs/ reltag>Acs/a>/li>											li>a hrefhttp://bphmeds.net/tag/atorvastatin/ reltag>Atorvastatin/a>/li>											li>a hrefhttp://bphmeds.net/tag/apo-hydro/ reltag>Apo-hydro/a>/li>											li>a hrefhttp://bphmeds.net/tag/aquazide-h/ reltag>Aquazide h/a>/li>											li>a hrefhttp://bphmeds.net/tag/dichlotride/ reltag>Dichlotride/a>/li>											li>a hrefhttp://bphmeds.net/tag/hydrodiuril/ reltag>Hydrodiuril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hydrosaluric/ reltag>Hydrosaluric/a>/li>											li>a hrefhttp://bphmeds.net/tag/microzide/ reltag>Microzide/a>/li>											li>a hrefhttp://bphmeds.net/tag/oretic/ reltag>Oretic/a>/li>											li>a hrefhttp://bphmeds.net/tag/moduretic/ reltag>Moduretic/a>/li>											li>a hrefhttp://bphmeds.net/tag/inderide/ reltag>Inderide/a>/li>											li>a hrefhttp://bphmeds.net/tag/dyazide/ reltag>Dyazide/a>/li>											li>a hrefhttp://bphmeds.net/tag/aldoril/ reltag>Aldoril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hctz/ reltag>Hctz/a>/li>											li>a hrefhttp://bphmeds.net/tag/hzt/ reltag>Hzt/a>/li>											li>a hrefhttp://bphmeds.net/tag/hydarazide/ reltag>Hydarazide/a>/li>											li>a hrefhttp://bphmeds.net/tag/clopidogrel/ reltag>Clopidogrel/a>/li>											li>a hrefhttp://bphmeds.net/tag/norvasc/ reltag>Norvasc/a>/li>											li>a hrefhttp://bphmeds.net/tag/tachycardia/ reltag>Tachycardia/a>/li>											li>a hrefhttp://bphmeds.net/tag/covera/ reltag>Covera/a>/li>											li>a hrefhttp://bphmeds.net/tag/hyperlipidemia/ reltag>Hyperlipidemia/a>/li>											li>a hrefhttp://bphmeds.net/tag/vastarel/ reltag>Vastarel/a>/li>											li>a hrefhttp://bphmeds.net/tag/preductal-mr/ reltag>Preductal mr/a>/li>											li>a hrefhttp://bphmeds.net/tag/vastarel-mr/ reltag>Vastarel mr/a>/li>											li>a hrefhttp://bphmeds.net/tag/vastarel-lm/ reltag>Vastarel lm/a>/li>											li>a hrefhttp://bphmeds.net/tag/vastarel-lp/ reltag>Vastarel lp/a>/li>											li>a hrefhttp://bphmeds.net/tag/preductal/ reltag>Preductal/a>/li>											li>a hrefhttp://bphmeds.net/tag/flavedon/ reltag>Flavedon/a>/li>											li>a hrefhttp://bphmeds.net/tag/flavedon-mr/ reltag>Flavedon mr/a>/li>											li>a hrefhttp://bphmeds.net/tag/cardaptan/ reltag>Cardaptan/a>/li>											li>a hrefhttp://bphmeds.net/tag/idaptan/ reltag>Idaptan/a>/li>											li>a hrefhttp://bphmeds.net/tag/carvidon/ reltag>Carvidon/a>/li>											li>a hrefhttp://bphmeds.net/tag/trizedon/ reltag>Trizedon/a>/li>											li>a hrefhttp://bphmeds.net/tag/trimetazidine/ reltag>Trimetazidine/a>/li>											li>a hrefhttp://bphmeds.net/tag/diltiazem-hcl/ reltag>Diltiazem hcl/a>/li>											li>a hrefhttp://bphmeds.net/tag/cardizem/ reltag>Cardizem/a>/li>											li>a hrefhttp://bphmeds.net/tag/dilacor/ reltag>Dilacor/a>/li>											li>a hrefhttp://bphmeds.net/tag/altiazem/ reltag>Altiazem/a>/li>											li>a hrefhttp://bphmeds.net/tag/tiamate/ reltag>Tiamate/a>/li>											li>a hrefhttp://bphmeds.net/tag/tildiem/ reltag>Tildiem/a>/li>											li>a hrefhttp://bphmeds.net/tag/adizem/ reltag>Adizem/a>/li>											li>a hrefhttp://bphmeds.net/tag/viazem/ reltag>Viazem/a>/li>											li>a hrefhttp://bphmeds.net/tag/dilatam/ reltag>Dilatam/a>/li>											li>a hrefhttp://bphmeds.net/tag/dilzem/ reltag>Dilzem/a>/li>											li>a hrefhttp://bphmeds.net/tag/zandil/ reltag>Zandil/a>/li>											li>a hrefhttp://bphmeds.net/tag/zemtrial/ reltag>Zemtrial/a>/li>											li>a hrefhttp://bphmeds.net/tag/diltelan/ reltag>Diltelan/a>/li>											li>a hrefhttp://bphmeds.net/tag/lipitor/ reltag>Lipitor/a>/li>											li>a hrefhttp://bphmeds.net/tag/torvast/ reltag>Torvast/a>/li>											li>a hrefhttp://bphmeds.net/tag/plavix/ reltag>Plavix/a>/li>											li>a hrefhttp://bphmeds.net/tag/fenofibrate/ reltag>Fenofibrate/a>/li>											li>a hrefhttp://bphmeds.net/tag/tricor/ reltag>Tricor/a>/li>											li>a hrefhttp://bphmeds.net/tag/coversyl/ reltag>Coversyl/a>/li>											li>a hrefhttp://bphmeds.net/tag/perindopril/ reltag>Perindopril/a>/li>											li>a hrefhttp://bphmeds.net/tag/aceon/ reltag>Aceon/a>/li>											li>a hrefhttp://bphmeds.net/tag/acertil/ reltag>Acertil/a>/li>											li>a hrefhttp://bphmeds.net/tag/armix/ reltag>Armix/a>/li>											li>a hrefhttp://bphmeds.net/tag/coverene/ reltag>Coverene/a>/li>											li>a hrefhttp://bphmeds.net/tag/coverex/ reltag>Coverex/a>/li>											li>a hrefhttp://bphmeds.net/tag/coversum/ reltag>Coversum/a>/li>											li>a hrefhttp://bphmeds.net/tag/prestarium/ reltag>Prestarium/a>/li>											li>a hrefhttp://bphmeds.net/tag/prexanil/ reltag>Prexanil/a>/li>											li>a hrefhttp://bphmeds.net/tag/prexum/ reltag>Prexum/a>/li>											li>a hrefhttp://bphmeds.net/tag/procaptan/ reltag>Procaptan/a>/li>											li>a hrefhttp://bphmeds.net/tag/atorlip/ reltag>Atorlip/a>/li>											li>a hrefhttp://bphmeds.net/tag/lipvas/ reltag>Lipvas/a>/li>											li>a hrefhttp://bphmeds.net/tag/sortis/ reltag>Sortis/a>/li>											li>a hrefhttp://bphmeds.net/tag/torvacard/ reltag>Torvacard/a>/li>											li>a hrefhttp://bphmeds.net/tag/totalip/ reltag>Totalip/a>/li>											li>a hrefhttp://bphmeds.net/tag/tulip/ reltag>Tulip/a>/li>											li>a hrefhttp://bphmeds.net/tag/lipittor/ reltag>Lipittor/a>/li>											li>a hrefhttp://bphmeds.net/tag/lipator/ reltag>Lipator/a>/li>											li>a hrefhttp://bphmeds.net/tag/liptor/ reltag>Liptor/a>/li>											li>a hrefhttp://bphmeds.net/tag/lisinopril/ reltag>Lisinopril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypokalemia/ reltag>Hypokalemia/a>/li>											li>a hrefhttp://bphmeds.net/tag/acne/ reltag>Acne/a>/li>											li>a hrefhttp://bphmeds.net/tag/migraine/ reltag>Migraine/a>/li>											li>a hrefhttp://bphmeds.net/tag/essential-tremor/ reltag>Essential tremor/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypertrophic-subaortic-stenosis/ reltag>Hypertrophic subaortic stenosis/a>/li>											li>a hrefhttp://bphmeds.net/tag/pheochromocytoma/ reltag>Pheochromocytoma/a>/li>											li>a hrefhttp://bphmeds.net/tag/inderal/ reltag>Inderal/a>/li>											li>a hrefhttp://bphmeds.net/tag/propranolol/ reltag>Propranolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/inderal-la/ reltag>Inderal la/a>/li>											li>a hrefhttp://bphmeds.net/tag/avlocardyl/ reltag>Avlocardyl/a>/li>											li>a hrefhttp://bphmeds.net/tag/deralin/ reltag>Deralin/a>/li>											li>a hrefhttp://bphmeds.net/tag/dociton/ reltag>Dociton/a>/li>											li>a hrefhttp://bphmeds.net/tag/inderalici/ reltag>Inderalici/a>/li>											li>a hrefhttp://bphmeds.net/tag/innopran-xl/ reltag>Innopran xl/a>/li>											li>a hrefhttp://bphmeds.net/tag/sumial/ reltag>Sumial/a>/li>											li>a hrefhttp://bphmeds.net/tag/anaprilinum/ reltag>Anaprilinum/a>/li>											li>a hrefhttp://bphmeds.net/tag/acute-coronary-syndrome/ reltag>Acute coronary syndrome/a>/li>											li>a hrefhttp://bphmeds.net/tag/peripheral-arterial-disease/ reltag>Peripheral arterial disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/liver-cirrhosis/ reltag>Liver cirrhosis/a>/li>											li>a hrefhttp://bphmeds.net/tag/heart-pain/ reltag>Heart pain/a>/li>											li>a hrefhttp://bphmeds.net/tag/toprol-xl/ reltag>Toprol xl/a>/li>											li>a hrefhttp://bphmeds.net/tag/lopressor/ reltag>Lopressor/a>/li>											li>a hrefhttp://bphmeds.net/tag/seleken/ reltag>Seleken/a>/li>											li>a hrefhttp://bphmeds.net/tag/selokeen/ reltag>Selokeen/a>/li>											li>a hrefhttp://bphmeds.net/tag/minax/ reltag>Minax/a>/li>											li>a hrefhttp://bphmeds.net/tag/betaloc/ reltag>Betaloc/a>/li>											li>a hrefhttp://bphmeds.net/tag/corvitol/ reltag>Corvitol/a>/li>											li>a hrefhttp://bphmeds.net/tag/toprol/ reltag>Toprol/a>/li>											li>a hrefhttp://bphmeds.net/tag/metoprolol/ reltag>Metoprolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/triglycerides/ reltag>Triglycerides/a>/li>											li>a hrefhttp://bphmeds.net/tag/adalat/ reltag>Adalat/a>/li>											li>a hrefhttp://bphmeds.net/tag/nifedipine/ reltag>Nifedipine/a>/li>											li>a hrefhttp://bphmeds.net/tag/nicardia/ reltag>Nicardia/a>/li>											li>a hrefhttp://bphmeds.net/tag/adalat-cc/ reltag>Adalat cc/a>/li>											li>a hrefhttp://bphmeds.net/tag/procardia-xl/ reltag>Procardia xl/a>/li>											li>a hrefhttp://bphmeds.net/tag/procardia/ reltag>Procardia/a>/li>											li>a hrefhttp://bphmeds.net/tag/nifedical/ reltag>Nifedical/a>/li>											li>a hrefhttp://bphmeds.net/tag/hyperaldosteronism/ reltag>Hyperaldosteronism/a>/li>											li>a hrefhttp://bphmeds.net/tag/adenoma/ reltag>Adenoma/a>/li>											li>a hrefhttp://bphmeds.net/tag/prinivil/ reltag>Prinivil/a>/li>											li>a hrefhttp://bphmeds.net/tag/hyperplasia/ reltag>Hyperplasia/a>/li>											li>a hrefhttp://bphmeds.net/tag/tensopril/ reltag>Tensopril/a>/li>											li>a hrefhttp://bphmeds.net/tag/zestril/ reltag>Zestril/a>/li>											li>a hrefhttp://bphmeds.net/tag/sodium-retention/ reltag>Sodium retention/a>/li>											li>a hrefhttp://bphmeds.net/tag/hipril/ reltag>Hipril/a>/li>											li>a hrefhttp://bphmeds.net/tag/carace/ reltag>Carace/a>/li>											li>a hrefhttp://bphmeds.net/tag/nephrotic-syndrome/ reltag>Nephrotic syndrome/a>/li>											li>a hrefhttp://bphmeds.net/tag/lisinopril-hctz/ reltag>Lisinopril hctz/a>/li>											li>a hrefhttp://bphmeds.net/tag/lisinaopril/ reltag>Lisinaopril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hirsutism/ reltag>Hirsutism/a>/li>											li>a hrefhttp://bphmeds.net/tag/aldactone/ reltag>Aldactone/a>/li>											li>a hrefhttp://bphmeds.net/tag/spironolactone/ reltag>Spironolactone/a>/li>											li>a hrefhttp://bphmeds.net/tag/novo-spiroton/ reltag>Novo-spiroton/a>/li>											li>a hrefhttp://bphmeds.net/tag/spiractin/ reltag>Spiractin/a>/li>											li>a hrefhttp://bphmeds.net/tag/spirotone/ reltag>Spirotone/a>/li>											li>a hrefhttp://bphmeds.net/tag/verospiron/ reltag>Verospiron/a>/li>											li>a hrefhttp://bphmeds.net/tag/berlactone/ reltag>Berlactone/a>/li>											li>a hrefhttp://bphmeds.net/tag/renal-disease/ reltag>Renal disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/irbesartan/ reltag>Irbesartan/a>/li>											li>a hrefhttp://bphmeds.net/tag/post-myocardial-infarction/ reltag>Post-myocardial infarction/a>/li>											li>a hrefhttp://bphmeds.net/tag/diovan/ reltag>Diovan/a>/li>											li>a hrefhttp://bphmeds.net/tag/valsartan/ reltag>Valsartan/a>/li>											li>a hrefhttp://bphmeds.net/tag/stroke-risk/ reltag>Stroke risk/a>/li>											li>a hrefhttp://bphmeds.net/tag/lasix/ reltag>Lasix/a>/li>											li>a hrefhttp://bphmeds.net/tag/furosemide/ reltag>Furosemide/a>/li>											li>a hrefhttp://bphmeds.net/tag/frusemid/ reltag>Frusemid/a>/li>											li>a hrefhttp://bphmeds.net/tag/frusid/ reltag>Frusid/a>/li>											li>a hrefhttp://bphmeds.net/tag/frusol/ reltag>Frusol/a>/li>											li>a hrefhttp://bphmeds.net/tag/frudix/ reltag>Frudix/a>/li>											li>a hrefhttp://bphmeds.net/tag/furosedon/ reltag>Furosedon/a>/li>											li>a hrefhttp://bphmeds.net/tag/frusenex/ reltag>Frusenex/a>/li>											li>a hrefhttp://bphmeds.net/tag/chronic-renal-failure/ reltag>Chronic renal failure/a>/li>											li>a hrefhttp://bphmeds.net/tag/micardis/ reltag>Micardis/a>/li>											li>a hrefhttp://bphmeds.net/tag/telmisartan/ reltag>Telmisartan/a>/li>											li>a hrefhttp://bphmeds.net/tag/pritor/ reltag>Pritor/a>/li>											li>a hrefhttp://bphmeds.net/tag/kinzal/ reltag>Kinzal/a>/li>											li>a hrefhttp://bphmeds.net/tag/telma/ reltag>Telma/a>/li>											li>a hrefhttp://bphmeds.net/tag/telday/ reltag>Telday/a>/li>											li>a hrefhttp://bphmeds.net/tag/teleact-d/ reltag>Teleact d/a>/li>											li>a hrefhttp://bphmeds.net/tag/mycardis/ reltag>Mycardis/a>/li>											li>a hrefhttp://bphmeds.net/tag/coronary-artery-disease/ reltag>Coronary artery disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/losartan/ reltag>Losartan/a>/li>											li>a hrefhttp://bphmeds.net/tag/diabetic-nephropathy/ reltag>Diabetic nephropathy/a>/li>											li>a hrefhttp://bphmeds.net/tag/bph/ reltag>Bph/a>/li>											li>a hrefhttp://bphmeds.net/tag/verapamil/ reltag>Verapamil/a>/li>											li>a hrefhttp://bphmeds.net/tag/isoptin/ reltag>Isoptin/a>/li>											li>a hrefhttp://bphmeds.net/tag/verelan/ reltag>Verelan/a>/li>											li>a hrefhttp://bphmeds.net/tag/verelan-pm/ reltag>Verelan pm/a>/li>											li>a hrefhttp://bphmeds.net/tag/calan/ reltag>Calan/a>/li>											li>a hrefhttp://bphmeds.net/tag/bosoptin/ reltag>Bosoptin/a>/li>											li>a hrefhttp://bphmeds.net/tag/clopitab/ reltag>Clopitab/a>/li>											li>a hrefhttp://bphmeds.net/tag/clopilet/ reltag>Clopilet/a>/li>											li>a hrefhttp://bphmeds.net/tag/ceruvin/ reltag>Ceruvin/a>/li>											li>a hrefhttp://bphmeds.net/tag/dyslipidemia/ reltag>Dyslipidemia/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypertriglyceridemia/ reltag>Hypertriglyceridemia/a>/li>											li>a hrefhttp://bphmeds.net/tag/altace/ reltag>Altace/a>/li>											li>a hrefhttp://bphmeds.net/tag/rampiril/ reltag>Rampiril/a>/li>											li>a hrefhttp://bphmeds.net/tag/tritace/ reltag>Tritace/a>/li>											li>a hrefhttp://bphmeds.net/tag/ramace/ reltag>Ramace/a>/li>											li>a hrefhttp://bphmeds.net/tag/lopace/ reltag>Lopace/a>/li>											li>a hrefhttp://bphmeds.net/tag/ramipril/ reltag>Ramipril/a>/li>											li>a hrefhttp://bphmeds.net/tag/fenofibric-acid/ reltag>Fenofibric acid/a>/li>											li>a hrefhttp://bphmeds.net/tag/lofibra/ reltag>Lofibra/a>/li>											li>a hrefhttp://bphmeds.net/tag/lipanthyl/ reltag>Lipanthyl/a>/li>											li>a hrefhttp://bphmeds.net/tag/fenocor-67/ reltag>Fenocor-67/a>/li>											li>a hrefhttp://bphmeds.net/tag/clonidine/ reltag>Clonidine/a>/li>											li>a hrefhttp://bphmeds.net/tag/catapres/ reltag>Catapres/a>/li>											li>a hrefhttp://bphmeds.net/tag/dixarit/ reltag>Dixarit/a>/li>											li>a hrefhttp://bphmeds.net/tag/adhd/ reltag>Adhd/a>/li>											li>a hrefhttp://bphmeds.net/tag/duraclone/ reltag>Duraclone/a>/li>											li>a hrefhttp://bphmeds.net/tag/arkamin/ reltag>Arkamin/a>/li>											li>a hrefhttp://bphmeds.net/tag/irregular-heart-rhythm/ reltag>Irregular heart rhythm/a>/li>											li>a hrefhttp://bphmeds.net/tag/chronic-stable-angina/ reltag>Chronic stable angina/a>/li>											li>a hrefhttp://bphmeds.net/tag/vasospastic-angina/ reltag>Vasospastic angina/a>/li>											li>a hrefhttp://bphmeds.net/tag/dailyvasc/ reltag>Dailyvasc/a>/li>											li>a hrefhttp://bphmeds.net/tag/perivasc/ reltag>Perivasc/a>/li>											li>a hrefhttp://bphmeds.net/tag/avacard/ reltag>Avacard/a>/li>											li>a hrefhttp://bphmeds.net/tag/intermittent-claudication/ reltag>Intermittent claudication/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypercholesterolemia/ reltag>Hypercholesterolemia/a>/li>											li>a hrefhttp://bphmeds.net/tag/rosulip-f/ reltag>Rosulip-f/a>/li>											li>a hrefhttp://bphmeds.net/tag/rosuvastatin/ reltag>Rosuvastatin/a>/li>											li>a hrefhttp://bphmeds.net/tag/crestor/ reltag>Crestor/a>/li>											li>a hrefhttp://bphmeds.net/tag/amlopres-at/ reltag>Amlopres-at/a>/li>											li>a hrefhttp://bphmeds.net/tag/fluid-retention/ reltag>Fluid retention/a>/li>											li>a hrefhttp://bphmeds.net/tag/ventricular-arrhythmia/ reltag>Ventricular arrhythmia/a>/li>											li>a hrefhttp://bphmeds.net/tag/urinary-outflow-obstruction/ reltag>Urinary outflow obstruction/a>/li>											li>a hrefhttp://bphmeds.net/tag/benign-prostatic-hyperplasia/ reltag>Benign prostatic hyperplasia/a>/li>											li>a hrefhttp://bphmeds.net/tag/cardura/ reltag>Cardura/a>/li>											li>a hrefhttp://bphmeds.net/tag/doxazosin/ reltag>Doxazosin/a>/li>											li>a hrefhttp://bphmeds.net/tag/carduran/ reltag>Carduran/a>/li>											li>a hrefhttp://bphmeds.net/tag/cascor/ reltag>Cascor/a>/li>											li>a hrefhttp://bphmeds.net/tag/doxadura/ reltag>Doxadura/a>/li>											li>a hrefhttp://bphmeds.net/tag/ventricular-dysfunction/ reltag>Ventricular dysfunction/a>/li>											li>a hrefhttp://bphmeds.net/tag/coreg/ reltag>Coreg/a>/li>											li>a hrefhttp://bphmeds.net/tag/carvedilol/ reltag>Carvedilol/a>/li>											li>a hrefhttp://bphmeds.net/tag/dilatrend/ reltag>Dilatrend/a>/li>											li>a hrefhttp://bphmeds.net/tag/eucardic/ reltag>Eucardic/a>/li>											li>a hrefhttp://bphmeds.net/tag/carloc/ reltag>Carloc/a>/li>											li>a hrefhttp://bphmeds.net/tag/chronic-atrial-fibrillation/ reltag>Chronic atrial fibrillation/a>/li>											li>a hrefhttp://bphmeds.net/tag/lanoxin/ reltag>Lanoxin/a>/li>											li>a hrefhttp://bphmeds.net/tag/digoxin/ reltag>Digoxin/a>/li>											li>a hrefhttp://bphmeds.net/tag/digitek/ reltag>Digitek/a>/li>											li>a hrefhttp://bphmeds.net/tag/digitalis/ reltag>Digitalis/a>/li>											li>a hrefhttp://bphmeds.net/tag/lanoxicaps/ reltag>Lanoxicaps/a>/li>											li>a hrefhttp://bphmeds.net/tag/amlopres-z/ reltag>Amlopres-z/a>/li>											li>a hrefhttp://bphmeds.net/tag/peripheral-vascular-disease/ reltag>Peripheral vascular disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/avapro/ reltag>Avapro/a>/li>											li>a hrefhttp://bphmeds.net/tag/aprovel/ reltag>Aprovel/a>/li>											li>a hrefhttp://bphmeds.net/tag/karvea/ reltag>Karvea/a>/li>											li>a hrefhttp://bphmeds.net/tag/betapace/ reltag>Betapace/a>/li>											li>a hrefhttp://bphmeds.net/tag/sotalol/ reltag>Sotalol/a>/li>											li>a hrefhttp://bphmeds.net/tag/sotalex/ reltag>Sotalex/a>/li>											li>a hrefhttp://bphmeds.net/tag/sotacor/ reltag>Sotacor/a>/li>											li>a hrefhttp://bphmeds.net/tag/caduet/ reltag>Caduet/a>/li>											li>a hrefhttp://bphmeds.net/tag/envacar/ reltag>Envacar/a>/li>											li>a hrefhttp://bphmeds.net/tag/co-diovan/ reltag>Co-diovan/a>/li>											li>a hrefhttp://bphmeds.net/tag/vf/ reltag>Vf/a>/li>											li>a hrefhttp://bphmeds.net/tag/valtan/ reltag>Valtan/a>/li>											li>a hrefhttp://bphmeds.net/tag/valzaar/ reltag>Valzaar/a>/li>											li>a hrefhttp://bphmeds.net/tag/isosorbide-mononitrate/ reltag>Isosorbide mononitrate/a>/li>											li>a hrefhttp://bphmeds.net/tag/imdur/ reltag>Imdur/a>/li>											li>a hrefhttp://bphmeds.net/tag/ismo/ reltag>Ismo/a>/li>											li>a hrefhttp://bphmeds.net/tag/monoket/ reltag>Monoket/a>/li>											li>a hrefhttp://bphmeds.net/tag/minipress/ reltag>Minipress/a>/li>											li>a hrefhttp://bphmeds.net/tag/prazosin/ reltag>Prazosin/a>/li>											li>a hrefhttp://bphmeds.net/tag/vasoflex/ reltag>Vasoflex/a>/li>											li>a hrefhttp://bphmeds.net/tag/hypovase/ reltag>Hypovase/a>/li>											li>a hrefhttp://bphmeds.net/tag/leg-pain/ reltag>Leg pain/a>/li>											li>a hrefhttp://bphmeds.net/tag/labetalol/ reltag>Labetalol/a>/li>											li>a hrefhttp://bphmeds.net/tag/chronic-occlusive-arterial-disease/ reltag>Chronic occlusive arterial disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/trental/ reltag>Trental/a>/li>											li>a hrefhttp://bphmeds.net/tag/pentoxifylline/ reltag>Pentoxifylline/a>/li>											li>a hrefhttp://bphmeds.net/tag/pentoxil/ reltag>Pentoxil/a>/li>											li>a hrefhttp://bphmeds.net/tag/triamterene/ reltag>Triamterene/a>/li>											li>a hrefhttp://bphmeds.net/tag/dyrenium/ reltag>Dyrenium/a>/li>											li>a hrefhttp://bphmeds.net/tag/benzthiazide/ reltag>Benzthiazide/a>/li>											li>a hrefhttp://bphmeds.net/tag/avalide/ reltag>Avalide/a>/li>											li>a hrefhttp://bphmeds.net/tag/azor/ reltag>Azor/a>/li>											li>a hrefhttp://bphmeds.net/tag/olmesartan/ reltag>Olmesartan/a>/li>											li>a hrefhttp://bphmeds.net/tag/benicar/ reltag>Benicar/a>/li>											li>a hrefhttp://bphmeds.net/tag/olmesartan-medoxomil/ reltag>Olmesartan medoxomil/a>/li>											li>a hrefhttp://bphmeds.net/tag/olmetec/ reltag>Olmetec/a>/li>											li>a hrefhttp://bphmeds.net/tag/zebeta/ reltag>Zebeta/a>/li>											li>a hrefhttp://bphmeds.net/tag/bisoprolol/ reltag>Bisoprolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/monocor/ reltag>Monocor/a>/li>											li>a hrefhttp://bphmeds.net/tag/zestoretic/ reltag>Zestoretic/a>/li>											li>a hrefhttp://bphmeds.net/tag/amiodarone/ reltag>Amiodarone/a>/li>											li>a hrefhttp://bphmeds.net/tag/left-ventricular-hypertrophy/ reltag>Left ventricular hypertrophy/a>/li>											li>a hrefhttp://bphmeds.net/tag/cozaar/ reltag>Cozaar/a>/li>											li>a hrefhttp://bphmeds.net/tag/cosart/ reltag>Cosart/a>/li>											li>a hrefhttp://bphmeds.net/tag/lotrel/ reltag>Lotrel/a>/li>											li>a hrefhttp://bphmeds.net/tag/benazepril-hydrochloride/ reltag>Benazepril hydrochloride/a>/li>											li>a hrefhttp://bphmeds.net/tag/amlodipine-besylate/ reltag>Amlodipine besylate/a>/li>											li>a hrefhttp://bphmeds.net/tag/lozol/ reltag>Lozol/a>/li>											li>a hrefhttp://bphmeds.net/tag/indapamide/ reltag>Indapamide/a>/li>											li>a hrefhttp://bphmeds.net/tag/natrilix/ reltag>Natrilix/a>/li>											li>a hrefhttp://bphmeds.net/tag/nebivolol/ reltag>Nebivolol/a>/li>											li>a hrefhttp://bphmeds.net/tag/nubeta/ reltag>Nubeta/a>/li>											li>a hrefhttp://bphmeds.net/tag/bystolic/ reltag>Bystolic/a>/li>											li>a hrefhttp://bphmeds.net/tag/poor-circulation/ reltag>Poor circulation/a>/li>											li>a hrefhttp://bphmeds.net/tag/pletal/ reltag>Pletal/a>/li>											li>a hrefhttp://bphmeds.net/tag/cilostazol/ reltag>Cilostazol/a>/li>											li>a hrefhttp://bphmeds.net/tag/ranolazine/ reltag>Ranolazine/a>/li>											li>a hrefhttp://bphmeds.net/tag/ranexa/ reltag>Ranexa/a>/li>											li>a hrefhttp://bphmeds.net/tag/hepatic-disease/ reltag>Hepatic disease/a>/li>											li>a hrefhttp://bphmeds.net/tag/torsemide/ reltag>Torsemide/a>/li>											li>a hrefhttp://bphmeds.net/tag/demadex/ reltag>Demadex/a>/li>											li>a hrefhttp://bphmeds.net/tag/trandate/ reltag>Trandate/a>/li>											li>a hrefhttp://bphmeds.net/tag/ventricular-fibrillation/ reltag>Ventricular fibrillation/a>/li>											li>a hrefhttp://bphmeds.net/tag/hemodynamically-unstable-ventricular-tachycardia/ reltag>Hemodynamically-unstable ventricular tachycardia/a>/li>											li>a hrefhttp://bphmeds.net/tag/cordarone/ reltag>Cordarone/a>/li>											li>a hrefhttp://bphmeds.net/tag/prostate-enlargement/ reltag>Prostate enlargement/a>/li>											li>a hrefhttp://bphmeds.net/tag/hytrin/ reltag>Hytrin/a>/li>											li>a hrefhttp://bphmeds.net/tag/terazosin/ reltag>Terazosin/a>/li>											li>a hrefhttp://bphmeds.net/tag/lotensin/ reltag>Lotensin/a>/li>											li>a hrefhttp://bphmeds.net/tag/benazepril/ reltag>Benazepril/a>/li>											li>a hrefhttp://bphmeds.net/tag/hyzaar/ reltag>Hyzaar/a>/li>									/ul>			/div>		/div>	/div>	div idfooter>		div classpageList>			ul>							/ul>		/div>		div idcopywright>			p idabout>				Buy Blood Pressure/Heart Drugs without Prescription is proudly powered by a hrefhttp://www.wordpress.org target_blank>WordPress/a> & a hrefhttp://spectrum-theme.com/ target_blank>Spectrum Theme/a> by a hrefhttp://www.ignacioricci.com target_blank>Ignacio Ricci/a>			/p>			p idcodeIsPoetry>Code is poetry/p>			script typetext/javascript srchttp://bphmeds.net/wp-includes/js/wp-embed.min.js?ver4.7.2>/script>		/div>	/div>div stylewidth:1px; height:1px; overflow:hidden>!--LiveInternet counter-->script typetext/javascript>!--document.write(a hrefhttp://www.liveinternet.ru/click +target_blank>img src//counter.yadro.ru/hit?t42.6;r+escape(document.referrer)+((typeof(screen)undefined)?:;s+screen.width+*+screen.height+*+(screen.colorDepth?screen.colorDepth:screen.pixelDepth))+;u+escape(document.URL)+;+Math.random()+ alt titleLiveInternet +border0 width31 height31>\/a>)//-->/script>!--/LiveInternet-->/div>/body>/html>

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > bphmeds.net

Is this malicious?

DNS Resolutions

Port 80